Related Experiment Video
Updated: Feb 8, 2026

Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors
Jens C Hahne1, Nicola Valeri1,2
1Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.
Abstract:
Non-coding RNAs are important regulators of gene expression and transcription. It is well established that impaired non-coding RNA expression especially the one of long non-coding RNAs and microRNAs is involved in a number of pathological conditions including cancer. Non-coding RNAs are responsible for the development of resistance to anticancer treatments as they regulate drug resistance-related genes, affect intracellular drug concentrations, induce alternative signaling pathways, alter drug efficiency via blocking cell cycle regulation, and DNA damage response. Furthermore, they can prevent therapeutic-induced cell death and promote epithelial-mesenchymal transition (EMT) and elicit non-cell autonomous mechanisms of resistance. In this review, we summarize the role of non-coding RNAs for different mechanisms resulting in drug resistance (e.g., drug transport, drug metabolism, cell cycle regulation, regulation of apoptotic pathways, cancer stem cells, and EMT) in the context of gastrointestinal cancers.
Insights
Non-coding RNAs, including long non-coding RNAs and microRNAs, drive cancer drug resistance by regulating key genes and pathways. Understanding these roles is crucial for overcoming treatment failure in gastrointestinal cancers.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Non-coding RNAs (ncRNAs) are critical regulators of gene expression.
- Dysregulated ncRNAs, particularly long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), are implicated in various pathologies, including cancer.
- ncRNAs play a significant role in the development of resistance to anticancer therapies.
Purpose of the Study:
- To review the multifaceted roles of ncRNAs in mediating drug resistance in gastrointestinal cancers.
- To elucidate the specific mechanisms by which ncRNAs contribute to therapeutic resistance.
Main Methods:
- Literature review of studies on non-coding RNAs and cancer drug resistance.
- Analysis of ncRNA involvement in mechanisms like drug transport, metabolism, cell cycle, apoptosis, cancer stem cells, and EMT.
- Focus on gastrointestinal cancer contexts.
Main Results:
- ncRNAs regulate genes involved in drug resistance.
- They influence intracellular drug concentrations and activate alternative signaling pathways.
- ncRNAs can prevent apoptosis, promote epithelial-mesenchymal transition (EMT), and mediate non-cell autonomous resistance.
Conclusions:
- Non-coding RNAs are key players in diverse drug resistance mechanisms within gastrointestinal cancers.
- Targeting ncRNAs presents a potential strategy to overcome therapeutic resistance.
- Further research into ncRNA functions can inform novel cancer treatment approaches.
More Related Videos
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
piRNA - Piwi-interacting RNAs
Nursing Code of Ethics
Anatomy of the Gastrointestinal System
Here's a detailed walkthrough of this complex system:

